Royal London Asset Management
TGTX icon

Royal London Asset Management’s TG Therapeutics TGTX Stock Holding History

Royal London Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		$261K Buy
+43,133
New +$351K ﹤0.01% 524
2016
Q1 		– Sell
-17,625
Closed -$211K – 540
2015
Q4 		$211K Buy
+17,625
New +$223K ﹤0.01% 556

Other funds holding TGTX

BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royal London Asset Management's TGTX Position: Q2 2016 in Review

Royal London Asset Management opened a new position in TG Therapeutics (TGTX) in Q2 2016: 43,133 shares worth $261K. The stake represents ﹤0.01% of the portfolio and ranks #524 among its holdings. This is a return to the name: Royal London Asset Management previously reported a position in TGTX as recently as Q4 2015.

Royal London Asset Management first reported a position in TGTX in Q4 2015 and has held it in 2 quarters since. 91 funds tracked by Wall St. Rank hold TGTX as of Q2 2016.

  • Royal London Asset Management held 43,133 shares of TG Therapeutics worth $261K as of Q2 2016.
  • TG Therapeutics was a new Royal London Asset Management position in Q2 2016.
  • TG Therapeutics made up ﹤0.01% of Royal London Asset Management's portfolio in Q2 2016, its #524 holding.
  • Royal London Asset Management first reported a position in TG Therapeutics in Q4 2015 and has held it in 2 quarters since.
  • 91 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2016.

Based on Royal London Asset Management's 13F filing for Q2 2016, filed 2 Aug 2016.